Beranda › Melanoma › New York › New York City
Uji klinis Melanoma di New York City, NY
38 studi untuk Melanoma mencari peserta di lokasi sekitar New York City (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- Memorial Sloan Kettering Hospital, New York
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Menerima pesertaFase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Menerima pesertaFase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Menerima peserta
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Menerima pesertaFase 2
- Local Institution - 0170, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Menerima pesertaFase 1
- NYU Langone, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Hospital, New York
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Menerima pesertaFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Menerima peserta
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Menerima pesertaFase 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- dan 2 lainnya
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Menerima pesertaFase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Menerima pesertaFase 2
- NYU Langone Health, New York
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Menerima pesertaFase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Menerima pesertaFase 1/2
- Call for Information (Investigational Site 0031), New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Menerima pesertaFase 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 2
- USA04-0, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Menerima pesertaFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Menerima pesertaFase 3
- Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
- Northwell Health Cancer Institute, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Menerima pesertaFase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Menerima pesertaFase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Menerima pesertaFase 3
- Memorial Sloan Kettering Cancer Center, New York
ACTengine® IMA203 Combined With mRNA-4203
Menerima pesertaFase 1
- Memorial Sloan Kettering Cancer Center, New York
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Menerima pesertaFase 2
- NYU Langone Health, New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, New York
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Menerima peserta
- Memorial Sloan Kettering Cancer Center, New York
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Weill Cornell Medicine-New York-Presbyterian Hospital, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Menerima pesertaFase 1/2
- NYU Langone Health, New York
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Menerima peserta
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Menerima pesertaFase 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Uji klinis Melanoma di kota lain
- Houston, TX59 studi
- Los Angeles, CA34 studi
- Nashville, TN33 studi
- Pittsburgh, PA31 studi
- Boston, MA26 studi
- Philadelphia, PA23 studi
- San Francisco, CA22 studi
- Durham, NC21 studi
- Salt Lake City, UT21 studi
- St. Louis, MO21 studi
- Columbus, OH21 studi
- Atlanta, GA21 studi
Studi lain di New York City
- Kanker Payudara136 studi
- Kanker Paru Non-Sel Kecil121 studi
- Kanker (semua jenis)109 studi
- Kanker Prostat103 studi
- Kanker Metastatik93 studi
- Kanker Kolorektal78 studi
- Kanker Ovarium69 studi
- Kanker Paru60 studi
- Mieloma Multipel60 studi
- Kanker Pankreas60 studi
- Kanker Endometrium52 studi
- Leukemia Mieloid Akut51 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.